Oxcarbazepine (Oxtellar XR) vs Oxcarbazepine (Trileptal)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline

Oxcarbazepine (Oxtellar XR)

Marketed by Supernus Pharmaceuticals

Approved in Epilepsysmall molecule
Partial signal

NCT00772603 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.

Reported efficacy

Percent Change in Seizure Rate (one year): Percent Change in Seizure Rate (one year): Oxcarbazepine XR -26.3 percentage of change in seizure rate (range -100 to 344.7) (not_applicable)

Result source: NCT00908349

Oxcarbazepine (Trileptal)

Marketed by Novartis

Approved in Epilepsysmall molecule
Weak signal

NCT00050934 · Phase 3 · completed

The study enrolled 132 participants and measured the clinical outcome of seizure-frequency change, but the registry does not document randomization, blinding, or a comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

ClinicalTrials.gov records no allocation or masking for this study; the publication reports a randomized, rater-blind, parallel-group design.

Reported efficacy

change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline): Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. (met)

Result source: NCT00050934

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOxcarbazepine (Oxtellar XR)Oxcarbazepine (Trileptal)
Seizure frequency, % change—Not reported—Not posted · NCT00050934
50% responder rate50% vs 34%+16 vs placebo2400 mg/day · wk 16 · n 109NCT00772603
1 other result
  • 44% vs 34% 1200 mg/day · wk 16 · n 111 · Phase 3 · secondary NCT00772603
—Not posted · NCT00050934
Seizure freedom—Not reported—Not posted · NCT00050934

Seizure frequency, % change

Oxcarbazepine (Oxtellar XR)
—Not reported
Oxcarbazepine (Trileptal)
—Not posted · NCT00050934

50% responder rate

Oxcarbazepine (Oxtellar XR)
50% vs 34%+16 vs placebo2400 mg/day · wk 16 · n 109NCT00772603
1 other result
  • 44% vs 34% 1200 mg/day · wk 16 · n 111 · Phase 3 · secondary NCT00772603
Oxcarbazepine (Trileptal)
—Not posted · NCT00050934

Seizure freedom

Oxcarbazepine (Oxtellar XR)
—Not reported
Oxcarbazepine (Trileptal)
—Not posted · NCT00050934
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Oxcarbazepine (Trileptal)
Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. NCT00050934 · Phase 3 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Oxcarbazepine (Oxtellar XR): 4 of 4 rows · Oxcarbazepine (Trileptal): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOxcarbazepine (Oxtellar XR)Oxcarbazepine (Trileptal)
Dropout rate
42.3%2400 mg/daya
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
32.8%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
16.4%
NCT00908349 · Phase 3 · monotherapy
14.6%b
NCT00975715 · Phase 2/3 · combination
show 5 more results
—Group 1 (Inducers) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
—Group 2 (Neutral [Control]) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
0%
NCT00900237 · Phase 1 · registry result, not featured evidence
—450 mg Bid
NCT01679002 · Phase 1 · registry result, not featured evidence
—
NCT01678976 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
30.1%2400 mg/daya
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
14.8%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
4.7%
NCT00908349 · Phase 3 · monotherapy
12.5%b
NCT00975715 · Phase 2/3 · combination
show 5 more results
—Group 1 (Inducers) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
—Group 2 (Neutral [Control]) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
—
NCT00900237 · Phase 1 · registry result, not featured evidence
—450 mg Bid
NCT01679002 · Phase 1 · registry result, not featured evidence
—
NCT01678976 · Phase 1 · registry result, not featured evidence
Serious AEs
8.1%2400 mg/daya
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
5.7%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
8.4%
NCT00908349 · Phase 3 · monotherapy
2.1%b
NCT00975715 · Phase 2/3 · combination
show 5 more results
0%Group 1 (Inducers) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
0%Group 2 (Neutral [Control]) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
0%
NCT00900237 · Phase 1 · registry result, not featured evidence
0%450 mg Bid
NCT01679002 · Phase 1 · registry result, not featured evidence
0%
NCT01678976 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
2400 mg/daya
dizziness 40.7% (placebo 14.9%)
headache 15.4% (placebo 7.4%)
vomiting 15.4% (placebo 9.1%)
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
1200 mg/day
dizziness 19.7% (placebo 14.9%)
somnolence 11.5% (placebo 9.1%)
diplopia 9.8% (placebo 4.1%)
NCT00772603 · Phase 3 · Epilepsy · phase 3
dizziness 15.4%
headache 11.2%
diplopia 9.3%
NCT00908349 · Phase 3 · monotherapy
b
somnolence 42.6% (placebo 9.8%)
nasopharyngitis 10.6% (placebo 17.6%)
vomiting 10.6% (placebo 5.9%)
NCT00975715 · Phase 2/3 · combination
show 5 more results
somnolence 75%
dizziness 56.3%
headache 50%
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
somnolence 80%
dizziness 66.7%
headache 60%
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
headache 100%
dizziness 85.7%
back pain 71.4%
NCT00900237 · Phase 1 · registry result, not featured evidence
450 mg Bid
dizziness 54.5%
somnolence 54.5%
frontal headache 18.2%
NCT01679002 · Phase 1 · registry result, not featured evidence
dizziness 23.1%
headache 23.1%
nodule subcutaneous 15.4%
NCT01678976 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Oxcarbazepine (Oxtellar XR)

Seizure 50 50% (n=109) vs 34% (n=117) placebo @ 16wk2400 mg/day
responder rate · % of participants
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
44% (n=111) vs 34% (n=117) placebo @ 16wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
Seizure Free 14% (n=111) vs 4% (n=117) placebo @ 16wk2400 mg/day
absolute value · percentage points
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
6% (n=109) vs 4% (n=117) placebo @ 16wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
Seizure Free 17% (n=88) vs 7% (n=109) placebo @ 12wk2400 mg/day
absolute value · percentage points
Maintenance
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
4% (n=97) vs 7% (n=109) placebo @ 12wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3

Focal Onset Seizures

Shared mechanism: Voltage-gated sodium channel · full Focal Onset Seizures pipeline

Oxcarbazepine (Oxtellar XR)

Marketed by Supernus Pharmaceuticals

Approved in Focal Onset Seizuressmall molecule
Partial signal

NCT00772603 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.

Reported efficacy

PCH(T), ITT (Change at 16 weeks (4wks Titration + 12 wks Maintenance) compared to Baseline): PCH(T), ITT (Change at 16 weeks (4wks Titration + 12 wks Maintenance) compared to Baseline): 2400mg/Day SPN-804 -42.9 percentage of change (range -100 to 212.8) | 1200mg/Day SPN-804 -38.2 percentage of change (range -100 to 556.1) | Placebo -28.7 percentage of change (range -100 to 333.6) (mixed)

Result source: NCT00772603

Oxcarbazepine (Trileptal)

Marketed by Novartis

Approved in Focal Onset Seizuressmall molecule
Partial signal

NCT00975715 · Phase 2/3 · completed

The study randomized 48 participants to TRI476 and 51 to placebo and was double-blind. Its primary clinical endpoint was change in seizure frequency, but statistical significance was not reported, so the trial provides useful controlled evidence without clearly establishing that the primary endpoint was met.

No aligned efficacy figure on record for this race.

Results for Focal Onset Seizures

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Oxcarbazepine (Oxtellar XR): no structured comparison results are available for Focal Onset Seizures.

Available safety results

Oxcarbazepine (Trileptal)

Dropout rate
14.6%
NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination
Discontinued due to AEs
12.5%
NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination
Serious AEs
2.1%
NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination
Most frequent reported AEs
somnolence 42.6% (placebo 9.8%)
nasopharyngitis 10.6% (placebo 17.6%)
vomiting 10.6% (placebo 5.9%)
NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Oxcarbazepine (Oxtellar XR)'s landscape · Oxcarbazepine (Trileptal)'s landscape